SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
FEMY

Femasys Inc (NASDAQ:FEMY)

US · Delayed Price · Currency is USD
Healthcare · Medical - Instruments & Supplies
$1.24+$0.00 (+0.00%)
 
Market cap
$10.7M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 18, 2021
Market Cap$10.73M-93.3%
Revenue (ttm)$1.97M-4.2%
Net Income-$12.66M+36.1%
EPS-$3.93+72.3%
Shares Out8.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume95,628
Open$1.28
Previous Close$1.24
Day's Range$1.21 - $1.29
52-Week Range$1.07 - $20.80
Betan/a
AnalystsBuy
Price Targetn/a
Earnings DateApr 1, 2027
-1.61% (1D)
No price history available.

About FEMY

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.

Address
3950 Johns Creek Court, Suwanee, GA, 30024, US
Market Cap
11 million
Employees
53
Industrial Classification
Medical - Instruments & Supplies

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$134.00K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From FEMY’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+0.00%
5 Days
-13.29%
1 Month
-24.85%
6 Months
-81.63%
1 Year
-93.26%

$FEMY stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in FEMY holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by FEMY's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

FEMY Estimated quarterly lobbying spending

Source: U.S. Senate LDA

FEMY Revenue by Segment or Geography

FEMY's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New FEMY patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to FEMY from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in FEMY

VXFVanguard Extended Market ETF$38.27K
VTIVanguard Morningstar Total Stock Market ETF$37.02K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from FEMY’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
53.14
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
5
Sells
0
Buy Value
$134.00K
Distinct Buyers
5

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.